기관회원 [로그인]
소속기관에서 받은 아이디, 비밀번호를 입력해 주세요.
개인회원 [로그인]

비회원 구매시 입력하신 핸드폰번호를 입력해 주세요.
본인 인증 후 구매내역을 확인하실 수 있습니다.

회원가입
서지반출
Methotrexate의 임상약동력학적 고찰
[STEP1]서지반출 형식 선택
파일형식
@
서지도구
SNS
기타
[STEP2]서지반출 정보 선택
  • 제목
  • URL
돌아가기
확인
취소
  • Methotrexate의 임상약동력학적 고찰
  • Review on the Clinical Pharmacokinetics of Methotrexate
저자명
최경업,Choi. Kyung Eob
간행물명
한국임상약학회지
권/호정보
1991년|1권 1호|pp.1-7 (7 pages)
발행정보
한국임상약학회
파일정보
정기간행물|
PDF텍스트
주제분야
기타
이 논문은 한국과학기술정보연구원과 논문 연계를 통해 무료로 제공되는 원문입니다.
서지반출

기타언어초록

Folates are involved in a variety of important biosynthesis by way of donating one carbon unit. Since folate metabolism was well understood a number of antifol have been developed. Among these antifols, aminopterin was first used in the treatment of childhood leukemia. However due to its toxicity and purity problems. it was immediately replaced by another antifols. methotrexate (MTX). MTX is shown to be active against various malignancies including leukemia breast cancer, osteogenic sarcoma, and head and neck cancer. Clinically, MTX therapy is divided into 3 categories. depeding on the dose administered; low-dose is defined as doses < $80;mg/m^2$ intermediate-dose as doses $geqq;80;mg/m^2$ and < $1000;mg/m^2$ and high-dose as doses $geqq;1000;mg/m^2$. Leucovorin should be administered to minimize MTX toxicities when MTX doses are greater than $80-100;mg/m^2$. The clinical pharmacokinetics (ADME) of MTX is discussed in this text.